Identification of novel compounds that inhibit S100P and RAGE binding as a new therapy for Pancreatic Cancer

Louise MacKenzie

Research output: Contribution to conferenceAbstract

184 Downloads (Pure)


Pancreatic adenocarcinoma (PDAC) is one of the most lethal human cancers with a 5-year survival of less than 5% due mostly to the lack of effective therapy and difficulty of detection at an early stage of development. Recent studies have shown a high prevalence of S100 proteins in PDAC, in particular the calcium-binding protein S100P. It has been proposed that the metastasis-promoting calcium-binding protein S100P, which possesses both intracellular and extracellular functions, activates key cell signaling pathways, including MAP kinase and nuclear factor NFκB pathways through its extracellular interaction with the receptor for advanced glycation end products (RAGE). The interaction between RAGE-S100P stimulates pancreatic tumor proliferation, survival, invasion and metastasis progression in vitro and tumor metastasis in vivo. Using computational chemistry methods, our laboratory have identified 87 novel compounds that prevent S100P binding to RAGE. Here in this talk we will outline the key challenges and methodology used to validate an ELISA to measure S100P and RAGE interaction. Our initial results highlight 22 new lead compounds that inhibit S100P-RAGE interaction, some of which have shown an ability to decrease pancreatic cell line growth. This work is supported by Worldwide Cancer Research and the University of Hertfordshire.
Original languageEnglish
Number of pages1
Publication statusPublished - Aug 2015
EventMolecular Medicine - London, United Kingdom
Duration: 24 Aug 201526 Aug 2015


ConferenceMolecular Medicine
Country/TerritoryUnited Kingdom


Dive into the research topics of 'Identification of novel compounds that inhibit S100P and RAGE binding as a new therapy for Pancreatic Cancer'. Together they form a unique fingerprint.

Cite this